Predictors of excessive short-acting β

Despite being linked to unfavourable outcomes, short-acting β To analyse the prevalence and predictors of SABA overuse and exacerbations in patients with asthma in a nationwide database of prescription purchase records. The prevalence of excessive SABA use (≥ 12 canisters) and overuse (≥ 3 canisters) was analysed among patients aged 18-64 years who purchased asthma medications in 2018. Predictors of excessive SABA use and SABA overuse were examined by quasi-Poisson regression. Negative binomial regression was used to study the association of excessive SABA use or overuse to the risk of asthma exacerbation defined as a prescription for oral corticosteroids. Of 91,763 patients with asthma, 42,189 (46%) were SABA users (mean age, 47 years; 58% female). Among them, 34% purchased ≥ 3 SABA canisters, and 6% purchased ≥ 12 canisters. The risk (risk ratio, 95% CI) of excessive SABA use was lower in patients with concomitant prescriptions for inhaled corticosteroids (0.41, 0.34-0.48) or inhaled corticosteroids and long-acting β Excessive SABA use is highly prevalent in asthma management, is associated with lack of prescriptions for inhaled corticosteroids, and substantially increases the exacerbation risk.

Informations de copyright

Copyright: © 2023 Termedia Sp. z o. o.

Déclaration de conflit d'intérêts

P. D¹browiecki received consultancy fees from GlaxoSmithKline, Sandoz, lecture fees from AstraZeneca, Polpharma, Berlin Chemie, Adamed, and financial or material grants for research from Novartis. D. Brzostek is a permanent employee of AstraZeneca. A. D¹browski received consultancy fees from AstraZeneca. R. Dobek received consultancy fees from AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline, lecture fees from AstraZeneca, Berlin Chemie, Boehringer Ingelheim, GlaxoSmithKline, and financial or material grants for research (as a clinical trial principal investigator) from Genentech-Roche, Gossammer Bio. R. Gawlik received lecture fees from AstraZeneca, HAL Allergy, ALK, Novartis, Chiesi, Allergopharma, Mylan. I. Kupryś-Lipińska received consultancy fees fromGlaxoSmithKline, AstraZeneca, Novartis, lecture fees from AstraZeneca, Chiesi, GlaxoSmithKline, Nexter, Novartis, financial or material grants for research from AstraZeneca, and congress fees from Zentiva. A. Mastalerz-Migas received consultancy and lecture fees from AstraZeneca. M. L. Kowalski received consultancy fees from AstraZeneca, GlaxoSmithKline, Uriach, lecture fees from AstraZeneca, GlaxoSmithKline, Sandoz, Chiesi, Novartis, Uriach, and financial or material grants for research from GlaxoSmithKline. The remaining authors declare no relevant conflict of interests.